Avalon Pharmaceuticals Reports Third Quarter 2007 Financial Results.GERMANTOWN, Md. -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX) today announced results for the three and nine months ended September 30, 2007. The Company reported no revenues in the third quarter of 2007 and a net loss of $5.4 million, or $0.32 per share. For the first nine months of 2007, revenues were $0.8 million and net loss was $16.6 million, or $1.13 per share. As of September 30, 2007, the Company had $33.4 million in cash, cash equivalents and marketable securities Marketable Securities Very liquid securities that can be converted into cash quickly at a reasonable price. Notes: Marketable securities are very liquid as they tend to have maturities less than one year, and the rate at which these securities can be bought or sold has . "We are pleased with the progress we made this quarter in our clinical, pre-clinical and collaboration programs," stated Kenneth C. Carter, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Avalon. "Our lead candidate, AVN AVN Aviation AVN Avenue AVN Adult Video News AVN Avascular Necrosis AVN Atrioventricular Node AVN Aviation Model (weather forecast model, now Global Forecast System) AVN Air Vanuatu (ICAO code) 944, continues to progress through Phase I and II clinical trials, we reported exciting progress in our pre-clinical programs at the recent AACR-NCI-EORTC Conference in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden , and our collaborations continue to go well." Recent Highlights * Patient enrollment continued in both the AVN944 Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I for hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. patients and the AVN944 Phase II (Part A) clinical trial for pancreatic patients. * Posters presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics showed that AvalonRx([R]), the Company's core technology, identified potent selective small molecule inhibitors for the Beta-catenin pathway that demonstrate significant tumor tumor: see neoplasm. inhibition in multiple animal models. * The Company reported in a poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics that the Company used AvalonRx([R]) to identify and characterize small molecule inhibitors for the c-Myc pathway. * Collaborations with Merck, Novartis and ChemDiv continue to progress. * Bradley Lorimier appointed Chairman of Board of Directors in August 2007. Lorimier is a co-founder of Avalon and has served as a member of the Board of Directors since December 1999. Financial Results No revenues were reported for the third quarter of 2007, compared to $1.1 million in the third quarter of 2006. Revenues for the nine months ended September 30, 2007 were $0.8 million, compared with $2.1 million in the first nine months of 2006. Revenues in 2007 were from collaboration with Novartis Institutes for Biomedical Research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. . Revenues in 2006 were from collaborations with Novartis Institutes for Biomedical Research, MedImmune and the University of Louisville See also
1. ^ [1] 2. ^ [2] URL accessed on June 8 2006 3. . Total costs and expenses from operations were $5.7 million in the third quarter of 2007, an increase of $0.6 million compared with the $5.1 million reported for the third quarter of 2006. Total costs and expenses were $18.2 million for the nine months ended September 30, 2007, compared with $15.6 million in the comparable period of 2006. The increases in 2007 were principally due to clinical trial costs related to AVN944, compensation expenses, consulting costs and laboratory supplies expenses. Net loss was $5.4 million for the three months ended September 30, 2007 compared with $3.7 million in the comparable three months of 2006. For the first nine months of 2007, net loss was $16.6 million, compared with $12.7 million in the first nine months of 2006. Lower revenues and higher costs in the 2007 periods resulted in the higher losses in 2007. As of September 30, 2007, the company had $33.4 million in cash, cash equivalents and marketable securities. Of that amount, $4.9 million was held in a restricted account to serve as collateral for long-term debt Long-Term Debt Loans and financial obligations lasting over one year. Notes: For example debts obligations such as bonds and notes which have maturities greater than one year would be considered long-term debt. . Conference Call & Webcast Information Avalon Pharmaceuticals' senior management will host a conference call on Thursday, November 8, 2007 at 8:00 a.m. (EST EST electroshock therapy. EST abbr. electroshock therapy ), to discuss the quarterly results and recent business highlights. Live audio of the conference call will be available by dialing 1-866-831-6267 (in the U.S.) and 617-213-8857 (internationally), and providing the participant passcode, 97788369. To access the call by live webcast, please visit the Investor Presentations section of our website at http://www.avalonrx.com or go directly to the webcast via the following URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. : http://ir.avalonrx.com/phoenix.zhtml?c=188250&p=irol-irhome. An archived version of the webcast will also be available for 90 days. About Avalon Pharmaceuticals Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon's lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx([R]) is the company's proprietary platform which is based on large-scale biomarker biomarker /bio·mark·er/ (bi´o-mahr?ker) 1. a biological molecule used as a marker for a substance or process of interest. 2. tumor marker. bi·o·mark·er n. 1. identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD. Forward Looking Statements This announcement contains, in addition to historical information, certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties, in particular, related to progress in our drug discovery programs and our collaborations, and clinical progress in the development of AVN944. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties including the risk that the discovery programs and collaborations may not be successful and that AVN944 will not progress successfully in its clinical trials, and other risks described in our SEC filings. There can be no assurance that our development efforts will succeed, that AVN944 will receive required regulatory clearance or, even if such regulatory clearance is received, that any subsequent products will ultimately achieve commercial success. The information in this Release should be read in conjunction with the Risk Factors set forth in our 2006 Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and updates contained in subsequent filings we make with the SEC. [TABLE OMITTED] [TABLE OMITTED] |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion